ClinicalTrials.gg
CompletedNCT02092090SSaSSUpdated Apr 8, 2021

China Salt Substitute and Stroke Study

An interventional study of Dietary sodium reduction in Stroke, sponsored by The George Institute. Completed at 5 sites in China. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by The George Institute · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
20,996
Allocation
Randomized
Sex
All
01

Study summary

The study is a large scale cluster randomised trial to evaluate the effects of sodium reduction based upon the use of salt substitute on the risk of stroke defined as the occurrence of stroke and stroke deaths. The corresponding null hypothesis that will be tested is that sodium reduction will have no effect upon stroke risk. The secondary objectives are to determine effects of sodium reduction on major vascular events and total mortality.

Read the detailed description

Lowering sodium intake and the use of salt substitute have been proved to lower blood pressure levels. Effects on the risks of vascular outcomes have not been defined in an adequately powered randomised trial. Rural Chinese are known to consume very large quantities of sodium and to suffer from very high rates of hypertension and stroke. This study is a large scale cluster randomised trial done in rural areas of China. The study will define the effects of a salt substitute-based sodium reduction strategy on the primary outcome of stroke. Secondary endpoints will include major cardiovascular events and total mortality. The study will be conducted in 600 rural villages across five Northern Chinese provinces and Tibet. The study will recruit 35 individuals at elevated risk of stroke from each village for a total of 21,000 participants. The participating villages will be randomised into intervention and control group with 1:1 allocation. Recruitment will prioritise individuals with a history of stroke but also include older individuals with high blood pressure. Follow up is scheduled for 5 years. Individuals in intervention villages will receive repeated dietary advice and a supply of low sodium salt substitute while individuals in control villages will receive dietary advice at baseline only. Every 6 months throughout follow-up each individual will be contacted by phone call to inquire about the occurrence of stroke, hospitalisation for any cause and diagnoses of any other serious illnesses. The interview will be structured and done by individuals masked to the randomised assignment of each individual. For all deaths identified and all events that might possibly be non-fatal strokes a home visit will be made. A series of process indicators including urinary sodium, urinary potassium, blood pressure, knowledge about sodium and use of salt substitute will also be measured on a random sample of at least 20 individuals drawn from a random selection of 60 villages at baseline and every year thereafter.

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • salt substitute
  • sodium reduction
  • stroke
  • cluster randomized trial
  • China
03

In context

Stroke

7,441 studies on the registry are indexed under Stroke; 2,012 are open to participants now.

This study's enrollment of 20,996 is above the median of 50 across 5,482 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

The George Institute is the lead sponsor of 56 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Disease history
  • Prior stroke and/or
  • Aged 60 years or over and with uncontrolled high blood pressure (systolic blood pressure >=140 millimeters of mercury (mmHg) at visit if on blood pressure lowering medication; systolic blood pressure>=160 millimeters of mercury (mmHg) if not on blood pressure lowering medication)
  • Ownership of a phone by the participant or a household member

Exclusion criteria

Exclusion Criteria:

  • Participant or family member is using a potassium-sparing diuretic
  • Participant or family member is using a potassium supplement
  • Participant or family member has serious renal impairment
  • Participant or family member has other reason for concern about use of salt substitute
  • Participant eats most meals outside the home
  • Participant is not expected to live longer than 6 months from the date of assessment as estimated by the village doctor
  • Another family member living in the same household has already been included in the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
20,996 participants (actual)

Study arms

  • No intervention
    Control

    Dietary advice at baseline only

  • Experimental
    Dietary sodium reduction

    Dietary advice and reduced-sodium added-potassium salt substitute

    Behavioral: Dietary sodium reduction

Interventions

  • BehavioralDietary sodium reduction

    Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute

    Also known as: Reduced-sodium added-potassium salt substitute

06

What researchers measure

Primary outcomes

  1. Stroke

    The primary outcome will be stroke defined according to standard criteria on the basis of an acute disturbance of focal neurological function and resulting in death or symptoms lasting more than 24 hours. Imaging, clinical and laboratory data will be collected wherever possible.

    Time frame: 5 years

Secondary outcomes

  1. Total major vascular events

    The composite of stroke, acute coronary syndrome or vascular death

    Time frame: 5 years

  2. Total mortality

    Time frame: 5 years

Other outcomes

  1. Blood Pressure

    Time frame: 5 years

  2. Urinary sodium excretion

    Time frame: 5 years

  3. Urinary Potassium

    Time frame: 5 years

  4. Knowledge about sodium and salt substitute

    Knowledge about sodium and salt substitute will be measured using the following questions at baseline and follow-up:. Is a high salt intake good for your health? Does how much salt you eat affect your blood pressure? Does how much salt you eat affect your risk of stroke? What is the daily recommended salt intake for adults? Do you try to reduce the amount of salt you eat? Do you eat pickled vegetables most days? Do you add salt to most meals? Do you add mono-sodium glutamate to most meals? Do you try to eat less of a food if it is very salty? Have you heard about low sodium salt? If yes,does your household use low-sodium salt?

    Time frame: 5 years

07

Study locations

5 sites
  • Hebei Province Centre for Disease Control and Prevention
    Shijiazhuang, Hebei 71000, China
  • China Medical Universtity
    Shenyang, Liaoning 110001, China
  • Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • Xi'an Jiaotong University
    Xi'an, Shaanxi 710049, China
  • Changzhi Medical Colledge
    Changzhi, Shanxi 046000, China
08

References and documents

Publications

  • Zhang X, Yin X, Yap ML, Li Q, Huang L, Liu Y, Zhou B, Li Z, Zhao Y, Sun J, Yu Y, Yan LL, Wu Y, Neal B, Tian M. Effect of sodium-reduced potassium-enriched salt substitutes on stomach cancer: the Salt Substitute and Stroke Study (SSaSS). BMC Med. 2025 Apr 23;23(1):236. doi: 10.1186/s12916-025-04068-0. PubMed 40264179 ↗
  • Ding X, Zhang X, Huang L, Xiong S, Li Z, Zhao Y, Zhou B, Yin X, Xu B, Wu Y, Neal B, Tian M, Yan LL. Salt Substitution and Recurrent Stroke and Death: A Randomized Clinical Trial. JAMA Cardiol. 2025 Apr 1;10(4):343-350. doi: 10.1001/jamacardio.2024.5417. PubMed 39908026 ↗
  • Wang F, Pi Y, Zhao Y, Zhang Y, Zhou B, Li Z, Sun J, Yu Y, Tian M, Yang M, Huang L, Song H, Neal B, Kissock KR. Effect of salt substitution on fracture-a secondary analysis of the Salt Substitute and Stroke Study (SSaSS). BMC Med. 2024 Sep 4;22(1):366. doi: 10.1186/s12916-024-03586-7. PubMed 39232779 ↗
  • Qi Z, Tang S, Hao Y, Li Y, Hao T, Yang H, Shen Y, Huang L, Tian M, Feng X, Li Z. Effect of salt substitute and antihypertensive medications among high cardiovascular risk patients: A sub-study of Salt Substitute and Stroke Study (SSaSS). J Clin Hypertens (Greenwich). 2024 Sep;26(9):1063-1072. doi: 10.1111/jch.14872. Epub 2024 Jul 16. PubMed 39012269 ↗
  • Yu J, Arnott C, Li Q, Di Tanna GL, Tian M, Huang L, Yin X, Zhang X, Pearson SA, Labarthe DR, Elliott P, Yan LL, Zhou B, Wu Y, Neal B. Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes. Hypertension. 2024 May;81(5):1031-1040. doi: 10.1161/HYPERTENSIONAHA.123.22410. Epub 2024 Mar 11. PubMed 38465623 ↗
  • Haghdoost F, Gnanenthiran SR, Shan S, Kaistha P, Huang L, Tian M, Liu Y, Yin X, Zhang X, Hao Z, Wu Y, Di Tanna GL, Neal B, Rodgers A. The effect of salt substitution on frequency and severity of headache: results from the SSaSS cluster-randomised controlled trial of 20,995 participants. Eur J Clin Nutr. 2024 May;78(5):401-406. doi: 10.1038/s41430-024-01419-7. Epub 2024 Feb 24. PubMed 38402353 ↗
  • Yin X, Paige E, Tian M, Li Q, Huang L, Yu J, Rodgers A, Elliott P, Wu Y, Neal B. The Proportion of Dietary Salt Replaced With Potassium-Enriched Salt in the SSaSS: Implications for Scale-Up. Hypertension. 2023 May;80(5):956-965. doi: 10.1161/HYPERTENSIONAHA.122.20115. Epub 2023 Jan 11. PubMed 36628969 ↗
  • Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, Zhang J, Tian M, Huang L, Li Z, Yu Y, Zhao Y, Zhou B, Sun J, Liu Y, Yin X, Hao Z, Yu J, Li KC, Zhang X, Duan P, Wang F, Ma B, Shi W, Di Tanna GL, Stepien S, Shan S, Pearson SA, Li N, Yan LL, Labarthe D, Elliott P. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021 Sep 16;385(12):1067-1077. doi: 10.1056/NEJMoa2105675. Epub 2021 Aug 29. PubMed 34459569 ↗
  • Li KC, Tian M, Neal B, Huang L, Yu J, Liu Y, Yin X, Zhang X, Wu Y, Li N, Elliott P, Yan L, Labarthe D, Hao Z, Shi J, Feng X, Zhang J, Zhang Y, Zhang R, Zhou B, Li Z, Sun J, Zhao Y, Yu Y, Si L, Lung T. Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS). BMJ Open. 2021 Jul 20;11(7):e045929. doi: 10.1136/bmjopen-2020-045929. PubMed 34285006 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Sep 2020, 73 months.

Of 2,859 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 73 months is above that.

Counting every sponsor, half of 2,988 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2014
First posted
Mar 19, 2014
StartActual
Jul 9, 2014
Primary completionActual
Sep 4, 2020
CompletionActual
Sep 4, 2020
Last update
Apr 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02092090
Lead sponsor
The George Institute
Collaborators
Peking University, Northwestern University, Imperial College London, China Medical University, China, Changzhi Medical College, Centers for Disease Control and Prevention, China, Ningxia Medical University, Xi'an Jiaotong University
Responsible party
Sponsor
First posted
Mar 19, 2014
Start date
Jul 9, 2014
Primary completion
Sep 4, 2020
Completion
Sep 4, 2020
Last update
Apr 8, 2021

Study contacts

Bruce C Neal, PhD
principal investigator · The George Institute for Global Health, Australia
Yangfeng Wu, PhD
principal investigator · The George Institute for Global Health at Peking University Health Science Centre
Darwin Labarthe, PhD
principal investigator · Northwestern University
Paul Elliott, PhD
principal investigator · School of Public Health, Imperial College London
Lijing L Yan, PhD
principal investigator · The George Institute for Global Health at Peking University Health Science Centre
Nicole Y Li, PhD
principal investigator · The George Institute for Global Health, Australia

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion